Kilitch Drugs to divest Ethiopian arm for $14 million
Kilitch Drugs is divesting its Ethiopian subsidiary, Kilitch Estro Biotech, for $14 million to HarmeeCare Pharmaceuticals. The company plans to use the proceeds to reduce debt and expand its pharmaceutical manufacturing operations in India.
Why it matters
This move highlights a strategic shift for Indian pharmaceutical firms focusing on domestic manufacturing capacity and financial deleveraging.
Kilitch Drugs to divest Ethiopian arm for $14 million The divestment will enable capital reallocation towards higher-growth opportunities in India, debt repayment and expansion of core pharmaceutical business HYDERABAD Kilitch Drugs (India) will divest its entire shareholding in Ethiopian subsidiary, Kilitch Estro Biotech PLC (KEB), to HarmeeCare Pharmaceuticals, an Ethiopian state-owned enterprise, in a transaction valued at $14 million. The transaction forms part of its broader strategy to optimise business portfolio, strengthen financial flexibility and accelerate investments in its pharmaceutical manufacturing operations in India. The divestment will enable capital reallocation towards higher-growth opportunities in India, debt repayment and expansion of core pharmaceutical business.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in